Factual summary — November 13
Germany's Merck KGaA raised its 2026 guidance for the third time, projecting annual sales of €21.5 billion–€21.9 billion and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of €6.2 billion–€6.4 billion. Third-quarter sales rose 5.8% to €5.63 billion, supported by its life-science and electronics businesses, while healthcare continued to face patent-expiration pressures. Under CEO Kai Beckmann, the company is reshaping its portfolio through planned acquisitions involving Bio-Techne and Silence Therapeutics and the proposed sale of contract drug-manufacturing operations to Lonza. These transactions remain subject to their respective completion conditions.
The Wall Street Journal
Wall Street Journal · November 13, 2026
Why it matters strategically
Merck's transformation connects three markets with different growth cycles, capital requirements, and competitive dynamics: life-science tools, pharmaceutical therapeutics, and semiconductor materials.
The issue is whether portfolio restructuring creates higher-quality earnings or simply shifts the company's exposure toward other capital-intensive and cyclical businesses.